376 results on '"Kelly, Ronan J."'
Search Results
2. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses
3. Mapping fireline intensity and flame height of prescribed gorse wildland fires
4. A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma
5. Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/Gastroesophageal Adenocarcinoma
6. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
7. Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer
8. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
9. Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
10. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis
11. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection
12. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
13. Sitravatinib combined with PD1 blockade enhances cytotoxic T-Cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma
14. Role of Immunotherapy in Gastroesophageal Cancers—Advances, Challenges and Future Strategies
15. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer
16. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
17. Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
18. Sitravatinib combined with PD-1 blockade enhances cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma.
19. Brave new world—new and emerging treatments for gastric cancer
20. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
21. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
22. Scientific Advances in Thoracic Oncology 2016
23. Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrettʼs Esophagus to Invasive Esophageal Adenocarcinoma
24. Abstract CT155: Long term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma
25. Abstract 3374: Circulating cell-free tumor DNA dynamics capture minimal residual disease with neoadjuvant immune checkpoint blockade plus chemoradiotherapy for patients with operable esophageal/gastroesophageal junction cancer
26. Abstract 3366: A machine learning approach to determine the cellular origin of variants in liquid biopsies
27. Supplementary Data from Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib
28. Supplementary Data from A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
29. Supplementary Table 1, Supplementary Figures 1-4 from A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations
30. Supplementary Methods, Figures 1-2 from A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
31. Supplementary Methods, Figures 1-3, Tables 1-5 from A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas
32. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
33. The emerging role of immunotherapy for esophageal cancer
34. Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma
35. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation
36. Abstract B60: Sitravatanib enhances immune checkpoint blockade in a de novo esophageal adenocarcinoma model
37. The Texas Immuno-Oncology Biorepository, a statewide biospecimen collection and clinical informatics system to enable longitudinal tumor and immune profiling
38. Multi-center matched cohort study of convalescent plasma for hospitalized patients with COVID-19
39. Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice
40. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care
41. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial
42. Challenges, Perceptions, and Readiness of Oncology Clinicians for the MACRA Quality Payment Program
43. Classical activation of microglia in CD200-deficient mice is a consequence of blood brain barrier permeability and infiltration of peripheral cells
44. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
45. Abstract 1973: Patients with operable esophageal cancer and improved responses to combined chemoradiotherapy and immunotherapy display distinct microbiome profiles enriched in multiple Bacteroides species
46. CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model
47. Immunotherapy in Upper GI Malignancies
48. Additional file 1 of Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma
49. Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
50. Scientific Advances in Lung Cancer 2015
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.